NCT07068620

Brief Summary

Cerebral small vessel disease (cSVD) is characterized by an alteration of the structure and function of small penetrating brain arteries. Highly prevalent in older individuals from the general population, it represents a leading cause of stroke and a major contributor to cognitive decline and risk of dementia. Better detection and management of covert cSVD would have a major impact on preventing disability and costs related to stroke, cognitive impairment and dementia. The aim of the present study is to identify novel electroencephalographic (EEG) biomarkers of the cognitive deficits associated with cSVD, and how these biomarkers and cognitive performance are affected by personalized cognitive training or transcranial alternating current stimulation (tACS), a non-invasvie brain stimulation technique.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
22mo left

Started Aug 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress29%
Aug 2025Mar 2028

First Submitted

Initial submission to the registry

July 4, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 16, 2025

Completed
22 days until next milestone

Study Start

First participant enrolled

August 7, 2025

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 7, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 7, 2028

Last Updated

February 2, 2026

Status Verified

July 1, 2025

Enrollment Period

2.6 years

First QC Date

July 4, 2025

Last Update Submit

January 30, 2026

Conditions

Keywords

Cognitive declinedementiastrokesmall vessel diseasehealthy brain agingelectroencephalographyneuromodulationtranscranial alternating current stimulationcognitive trainingcognitive rehabilitation

Outcome Measures

Primary Outcomes (1)

  • EEG signal power

    The primary outcome measure is the average EEG signal power (across different frequency bands and for various electrodes) between the two participant groups with either minor or extensive cSVD

    Day 0, Day 26, Day 33

Study Arms (2)

Personalized cognitive training using an AI algorithmwith a non-linear learning path adapted to each

EXPERIMENTAL

Personalized cognitive training using an AI algorithm (zone of proximal development and empirical success - ZPDES - multi-arm algorithm), with a non-linear learning path adapted to each participant.

Device: Home-based cognitive training

Traditional cognitive training

ACTIVE COMPARATOR

Traditional cognitive training using a "staircase" method, featuring a linear progression.

Device: Home-based cognitive training

Interventions

All interventions will be carried out for both groups of participants, with either minimal or extensive cSVD. Upon enrollment, each participant will undergo two hospital visits (visit 1 at day 0, visit 2 at day 7), followed by a home-based cognitive training across 10 days (days 15-24), two more hospital visits (visit 3 at day 26, visit 4 at day 33), and finally a follow-up cognitive testing at home after 6 months.

Personalized cognitive training using an AI algorithmwith a non-linear learning path adapted to eachTraditional cognitive training

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients included or previously included in the SHIVA cohort
  • Basic computer skills (ability to open a browser, use a mouse and keyboard)
  • Access to a personal computer with an internet connection
  • Independent in Activities of Daily Living (ADL) with a score ≥ 5/6, and in Instrumental Activities of Daily Living (IADL) with a score ≥ 4/8
  • Informed and written consent signed by the participant and the investigating physician for this study

You may not qualify if:

  • Motor impairments preventing the use of a keyboard and mouse (e.g., motor issues related to severe hand osteoarthritis)
  • Depressive symptoms indicated by a score of 2 to 4 on the mini Geriatric Depression Scale (mini GDS), which includes 4 items
  • Age-related macular degeneration (AMD)
  • Untreated glaucoma
  • Untreated psychiatric conditions that interfere with cognitive assessments
  • Diagnosed attention deficit disorder with or without hyperactivity or patients who could not complete all cognitive tests required in the SHIVA cohort
  • Systemic diseases that cause cognitive changes, such as obesity and metabolic disorders
  • History of epilepsy or seizures
  • Scalp sensitivity or skin lesions (dermatitis, wounds, etc.)
  • Contraindications for the use of electrical stimulation:
  • Surgical clips, metal sutures, staples, stents
  • Osteosynthesis material in the head or neck
  • Pacemaker
  • Implanted hearing aid
  • Ocular foreign bodies, shrapnel, bullets
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Bordeaux, Hôpital Pellegrin, Unité Neurovasculaire

Bordeaux, 33000, France

RECRUITING

MeSH Terms

Conditions

Cerebral Small Vessel DiseasesStrokeCognitive DysfunctionDementia

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesCognition DisordersNeurocognitive DisordersMental Disorders

Central Study Contacts

IGOR SIBON, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 4, 2025

First Posted

July 16, 2025

Study Start

August 7, 2025

Primary Completion (Estimated)

March 7, 2028

Study Completion (Estimated)

March 7, 2028

Last Updated

February 2, 2026

Record last verified: 2025-07

Locations